The influence of immunosuppressants on direct-acting antiviral therapy is dependent on hepatitis C virus genotype

Abstract

Background

Direct-acting antivirals (DAA) have substantially increased sustained virological response rates after liver transplantation, with improved tolerance compared to interferon-based therapy. The influence of immunosuppressive agents on the efficacy of DAAs has not been clarified.

Methods

Subgenomic HCV replicons for genotype (GT) 1b, 2b, 3a and 4a were treated with the mammalian target of rapamycin (mTOR) inhibitors everolimus and sirolimus or with the calcineurin inhibitors (CNI) cyclosporine or tacrolimus, either alone or in combination with selected DAAs. Cell proliferation-related effects were excluded with MTT assays. HCV replication activity was quantified by quantitative real-time polymerase chain reaction or luciferase assay.

Results

Addition of either mTOR inhibitor to the DAA daclatasvir resulted in a 30% increase in antiviral activity compared to daclatasvir alone for HCV GT2a, GT3a and GT4a (all P ≤0.01). Similar results were obtained using sofosbuvir and ledipasvir. In contrast, addition of either mTOR inhibitor to daclatasvir induced a 30% reduction in antiviral activity in GT1b cells (P≤ .01 versus daclatasvir alone). Neither CNI affects the antiviral activity of the DAAs in any HCV GT.

Conclusion

For patients with HCV GT2a, GT3a or GT4a infection, mTOR-based immunosuppressive therapy may be beneficial, whereas CNI-based therapy may be more efficacious in GT1b patients.

This article is protected by copyright. All rights reserved.

from ! ORL Sfakianakis via paythelady.61 on Inoreader http://ift.tt/2zDsqdq
via IFTTT